Corium and Gurnet Point Capital Announce Manufacturing Business Acquisition and a $100 Million Neuroscience Therapeutics Investment by Webster Equity Partners, Establishing Two Independent Growth Companies
Copyright 2022, Business Wire.
news
2022-10-20 13:00:00

October 20, 2022 09:00 AM Eastern Daylight Time BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Corium, LLC ('Corium'), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital ('Gurnet Point'), a private investment firm focused on the healthcare and life sciences sectors, today announced the acquisition of their manufacturing business and a $100 million equity investment by Webster Equity Partners ('Webster'), a healthcare-focused private equity firm that focuses on applying its expertise in the health care services sector to drive sustainability and long term value.
